Vaccines are one of the most effective tools we have for protecting our health. They have a long track record of safety and efficacy and savings across the health system, and are responsible for significant improvements in public health, including the eradication of smallpox and the near elimination of diseases like polio and measles.
Now a new report from the World Health Organization (WHO) puts a spotlight on yet another downstream benefit of vaccines – their ability to lower antibiotic use, decrease resources spent treating resistant infections and reduce the global burden of antimicrobial resistance (AMR). Data show:
- Vaccines targeting 23 pathogens could reduce the number of antibiotics needed by 22% every year. People who are vaccinated tend to stay healthier and out of the hospital, preventing secondary infections that may need antimicrobial medicines.
- Existing vaccines for pneumococcal pneumonia, Haemophilus influenzae type B and typhoid could avert up to 106,000 deaths associated with AMR each year. An additional 543,000 AMR-linked deaths could be prevented annually if vaccines in development for tuberculosis and Klebsiella pneumoniae are ultimately successful in reaching approval and rolled out globally to patients.
Increasing vaccine uptake can also drive substantial savings for the health care system – globally and here in the U.S.
- According to the same WHO report, the global hospital costs of treating resistant pathogens are estimated at $730 billion each year. Vaccines, if rolled out for all 23 evaluated pathogens in the WHO research, could save one-third of the hospital costs associated with AMR.
- The U.S. Centers for Disease Control and Prevention (CDC) estimates that over the last 30 years in the United States, childhood vaccines have saved nearly $2.2 trillion in health care related costs.
- Vaccines can reduce the risk and severity of vaccine-preventable diseases like flu, pneumococcal disease, shingles and whooping cough, which cost $27 billion in direct and indirect costs each year among adults over the age of 50.
Absent intervention, AMR could result in 39 million deaths between now and 2050, according to The Lancet. But thanks to the U.S. biopharmaceutical industry’s leading efforts to research and develop innovative vaccine technology, these powerful tools are protecting Americans and people around the globe from disease and helping mitigate the threat of long-term public health challenges like AMR.
Learn more about AMR here.
Andrew Powaleny
Andrew Powaleny is the Deputy Vice President of Public Affairs at PhRMA, where he leads communications on scientific, regulatory and intellectual property issues, highlighting the biopharmaceutical industry’s efforts in developing innovative medicines and vaccines while promoting an environment that encourages necessary risk-taking. For five years starting in 2019, he launched and led PhRMA’s grassroots initiative, Voters for Cures, bringing patients and caregivers together to advocate for access to medicine and biopharmaceutical innovation. He also co-founded and co-chaired PRIDE Umbrella, a resource group for LGBTQ+ individuals. Prior to joining PhRMA in 2015, Andrew worked as a communications consultant in Washington, D.C., and as Deputy Press Secretary for the U.S. House Committee on Energy and Commerce under Chairman Fred Upton. He holds a degree in public policy and government from Eastern Connecticut State University, with a minor in music. Outside of work, Andrew enjoys exercise, musical theater and mentoring college students through The Fund for American Studies alumni association.
Andrew Powaleny
Why smart vaccine policy matters
New study: HPV vaccination helps prevent cervical cancer deaths
New research reinforces the importance of hepatitis B vaccination at birth
World Immunization Week: Putting preventable diseases in the past
Leveraging the power of vaccines to prevent antimicrobial resistance
Antimicrobial Resistance
Vaccines
Leveraging the power of vaccines to prevent antimicrobial resistance
Leveraging the power of vaccines to prevent antimicrobial resistance